Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BridgeBio Pharma, Inc. Director's Dealing 2025

May 10, 2025

30604_dirs_2025-05-09_67e52fe9-00f9-4f86-9b72-941cced2c870.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-05-07

Reporting Person: MCCORMICK FRANK (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-05-07 Common Stock G 33000 Disposed 79686 Direct
2025-05-08 Common Stock G 3000 Disposed 76686 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 979979 Indirect